---
title: "Huafu Securities: Maintains \"Buy\" rating on NKF, short-term fluctuations in Q1 2025 do not change long-term growth characteristics"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/241974833.md"
description: "Huafu Securities maintains a \"Buy\" rating on NKF, expecting a net profit attributable to the parent company of 826 million yuan in 2024, a year-on-year increase of 536.09%. Although the net profit attributable to the parent company for the first quarter of 2025 is expected to be 85 million yuan, a year-on-year decrease of 52.19%, short-term fluctuations do not affect long-term growth. The company is actively seeking external cooperation and has reached strategic partnerships with Hainan Shuangcheng and Tonghua Dongbao. Future approvals of biosimilars in the U.S. market will boost overseas business growth"
datetime: "2025-05-27T09:19:22.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/241974833.md)
  - [en](https://longbridge.com/en/news/241974833.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/241974833.md)
generator: "portal-rs"
---

# Huafu Securities: Maintains "Buy" rating on NKF, short-term fluctuations in Q1 2025 do not change long-term growth characteristics

HuaFu Securities research report points out that NKF achieved a net profit attributable to the parent company of 826 million yuan in 2024, an increase of 536.09% year-on-year; in Q1 2025, it achieved a net profit attributable to the parent company of 85 million yuan, a decrease of 52.19% year-on-year. The performance in 2024 meets expectations, and the short-term fluctuations in Q1 2025 do not change the long-term growth nature. In recent years, the company has actively sought external cooperation, successively reaching strategic partnerships with Hainan Shuangcheng and Tonghua Dongbao, obtaining exclusive commercialization rights for three products: albumin paclitaxel, glargine, and aspart and lispro insulins in the U.S. market. In the future, as biosimilars are approved in the U.S. market, it is expected to help the overseas formulation business grow rapidly. Considering the company as a rapidly transforming heparin raw material enterprise, the rapid growth of overseas injectable formulations and the potential contribution of biosimilars going abroad are expected to significantly increase performance in 2025-2026, maintaining a "buy" rating

### Related Stocks

- [603707.CN](https://longbridge.com/en/quote/603707.CN.md)
- [600867.CN](https://longbridge.com/en/quote/600867.CN.md)

## Related News & Research

- [03:39 ETWalovi Accelerates Global Push with WALOVI Singapore HQ Launch and Trio of Southeast Asia Deals](https://longbridge.com/en/news/297003145.md)
- [Vector Science begins pharma-grade peptide production at first LyoGenesis suite, targets 55,000 vials a month](https://longbridge.com/en/news/296780586.md)
- [DEA restricts three synthetic kratom compounds citing public safety threat](https://longbridge.com/en/news/296934498.md)
- [Predict signs Italy healthcare distribution deal for Robocore’s “temi” service robots](https://longbridge.com/en/news/296769892.md)
- [Orum Therapeutics Announces U.S. FDA Clearance of an IND Application for ORM-1153, a Novel CD123-GSPT1 Degrader-Antibody Conjugate](https://longbridge.com/en/news/296689195.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**